At a glance
ClinicalIndex Comparison RecordEarly Ph 1Completed· 30 enrolled
Drug / intervention
Anti-tumor Bdrug
Likely dose
Anti-tumor B 1,200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Inhibition of Oral Tumorigenesis by Antitumor B
In Brief
A Early Phase 1 clinical trial evaluating Anti-tumor B for Squamous Cell Cancer of the Oral Cavity. Completed, enrolled 30 participants across 1 site.
Detailed Summary
This is a window of opportunity study of Anti-tumor B (ATB). Anti-tumor B is a botanical agent composed of six Chinese herbs: Sophora tonkinensis, Polygonum bistorta, Prunella vulgaris, Sonchus brachyotus, Dictamnus dasycarpus, and Dioscorea bulbifera.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSquamous Cell Cancer of the Oral Cavity
CountriesUnited States
Collaborators--
Timeline
Early Ph 1CompletedFinished
2020202120222023202420252026
First PostedFeb 2020
Enrollment StartApr 2022
Primary CompletionMay 2025
Study CompletionJun 2025
TodayJul 2026
First PostedFeb 20, 2020
Enrollment StartApr 22, 2022
Primary CompletionMay 19, 2025
Study CompletionJun 5, 2025
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 6.4 years ago
Interventions
Anti-tumor Bdrug
1,200 mg, three times a day for seven to 28 days (dependent on scheduled surgery).